desoximetasone 2.5 mg/g Ointment — NDC 72578-095-01 (Billing 72578-0095-01)
This is a package of desoximetasone 2.5 mg/g Ointment from Viona Pharmaceuticals Inc, marketed since Oct 2020 and currently FDA-listed; retail pharmacies pay about $0.3686 per g (NADAC).
NDC database record
One package, one record: these facts belong to NDC 72578-095-01 alone.
- Record
- FDA NDC Directory package listing · Human prescription drug
- Code segments
- 72578 labeler · 095 product · 01 package
- Package marketed since
- Oct 23, 2020
- Sample package
- No — commercial package
- Listing certified through
- Dec 31, 2026
- Barcode (UPC)
- 0372578095017
- Medicaid fills, this package
- 52 prescriptions in the last four reported quarters
- FDA record last changed
- Jul 24, 2026
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification
- GSN (GCN sequence number): 007584
- GCN: 30800
- GPI-14 (Medi-Span): 90550040004205
- HICL (First Databank): 003309
- AHFS class code: 84:06.08.00
- RxCUI (RxNorm): 197575
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- FDA label on DailyMed · label index refreshed Oct 3, 2026
- RxNorm (NLM RxNav) · catalog refreshed Oct 1, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Oct 1, 2026
RxNorm drug class
This medicine belongs to the Corticosteroid class.
Where does this data come from?
- RxClass (NLM) · catalog refreshed Oct 1, 2026
Clinical
- It depends on the product. Creams, gels and ointments calm inflamed, itchy skin from conditions that respond to steroids. The spray is used for plaque psoriasis in adults 18 and ol...
- You put a thin film on the affected skin, usually twice a day, and rub it in gently. Don't cover the spray area with a bandage unless your doctor tells you to. Keep it away from yo...
- Stop when your skin is under control. The label doesn't recommend using the spray beyond 4 weeks. Avoid your face, armpits and groin, and don't use it on skin that has thinned.
- The most common are dryness, irritation and itching where you apply it. Call your doctor if you notice vision changes, thinning skin, stretch marks, or signs of infection.
Patient education
Supplement & herbal interactions
Some supplements/herbs that may interact with Desoximetasone — tap one for details:
Where does this data come from?
- MedlinePlus (NLM) · refreshed Oct 1, 2026
- FDA label on DailyMed · label index refreshed Oct 3, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per g | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | $0.369 | $5.53 / 15 g |
| Medicaid paysCMS SDUD · 12 mo | $0.8425 | $12.64 / 15 g |
| Medicare drug plans payPart D · Q2 2026 | $0.7262 | $10.89 / 15 g |
Where does this data come from?
- CMS NADAC weekly file · file of Sep 30, 2026
- CMS ASP pricing files · refreshed Sep 20, 2026
- CMS Medicaid State Drug Utilization Data · through Q1 2026
- CMS Part D plan pricing files · refreshed Sep 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Per unit | Per pack | Marketing start | Marketing end | Status |
|---|---|---|---|---|---|---|
| 72578-0095-01 You're viewing this | 1 TUBE in 1 CARTON / 15 g in 1 TUBE | $0.3686 / g | $5.53 | 2020-10-23 | — | Active |
| 72578-0095-02 72578-095-02 Main listing | 1 TUBE in 1 CARTON / 60 g in 1 TUBE | $0.2000 / g | $12.00 | 2020-10-23 | — | Active |
| 72578-0095-03 72578-095-03 | 1 TUBE in 1 CARTON / 100 g in 1 TUBE | $1.06 / g | $105.56 | 2020-10-23 | — | Active |
Per g, this pack runs about 84% above the cheapest pack (NDC 72578-0095-02, $0.2000 vs $0.3686 NADAC).
This pack accounts for about 25% of this product's recent Medicaid fills; most go to a different pack size. See all packs ↓
Pack size FAQ
What quantity is in this package?
What NDC number is used to bill for this package of desoximetasone 2.5 mg/g Ointment?
Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Desoximetasone 2.5 mg/g 00472-0479-15 | Actavis | 1 tube | $0.369 | AB | Availability likely | — |
| desoximetasone 2.5 mg/g 45802-0496-14 | Padagis | 1 tube | $0.369 | AB | Availability likely | — |
| Desoximetasone 2.5 mg/g 68180-0946-01 | Lupin | 1 tube | $0.369 | AB | Availability likely | — |
| desoximetasone 2.5 mg/gthis 72578-0095-01 | Viona | 1 tube | $0.369 | AB | Availability likely | — |
| Desoximetasone 2.5 mg/g 00472-0478-15 | Actavis | 1 tube | $0.394 | — | Discontinued | +7% |
| desoximetasone 2.5 mg/g 72578-0091-01 | Viona | 1 tube | $0.398 | AB | Availability likely | +8% |
| Desoximetasone 2.5 mg/g 45802-0495-35 | Padagis | 1 tube | $0.398 | AB | Availability likely | +8% |
| Desoximetasone 2.5 mg/g 68180-0950-01 | Lupin | 1 tube | $0.398 | AB | Availability likely | +8% |
| Desoximetasone 2.5 mg/g 71656-0087-15 | Saptalis | 15 tubes | $0.398 | AB | Availability likely | +8% |
| Desoximetasone 2.5 mg/g 51672-1270-01 | Sun | 1 tube | $0.410 | AB | Availability likely | +11% |
| Desoximetasone 2.5 mg/g 51672-1262-01 | Sun | 1 tube | $0.680 | — | FDA listed | +84% |
| Desoximetasone 2.5 mg/g 68462-0531-17 | Glenmark | 15 g | $0.680 | — | FDA listed | +84% |
| Desoximetasone 2.5 mg/g 40032-0024-60 | Novel | 1 tube | — | AB | FDA listed | — |
| desoximetasone 2.5 mg/g 63629-8641-01 | Bryant | 1 tube | — | AB | FDA listed | — |
| desoximetasone 2.5 mg/g 63629-8642-01 | Bryant | 1 tube | — | AB | FDA listed | — |
| desoximetasone 2.5 mg/g 70771-1166-00 | Zydus | 1 tube | — | AB | FDA listed | — |
| desoximetasone 2.5 mg/g 72162-1414-02 | Bryant | 1 tube | — | AB | FDA listed | — |
| Desoximetasone 2.5 mg/g 63187-0646-15 | Proficient | 1 tube | — | AB | FDA listed | — |
| Desoximetasone 2.5 mg/g 71205-0271-15 | Proficient | 1 tube | — | — | FDA listed | — |
| Desoximetasone 2.5 mg/g 50090-5571-00 | A-S | 1 tube | — | AB | FDA listed | — |
| Desoximetasone 2.5 mg/g 50090-0597-00 | A-S | 1 tube | — | AB | FDA listed | — |
| Desoximetasone 2.5 mg/g 72162-2330-02 | Bryant | 1 tube | — | AB | FDA listed | — |
| desoximetasone 2.5 mg/g 70771-1437-00 | Zydus | 1 tube | — | AB | FDA listed | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- FDA Orange Book · refreshed Oct 3, 2026
- CMS NADAC weekly file · file of Sep 30, 2026
Availability & generic status
This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.
Where does this data come from?
- FDA Orange Book · refreshed Oct 3, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII Q9L0O73W7L
Coconut oil is a natural fat extracted from coconut fruit. It's used in medicines as a lubricant, emollient, or carrier to help dissolve or deliver active ingredients smoothly through the formulation.
-
UNII 4T6H12BN9U
Petrolatum is a purified mineral oil-based jelly derived from petroleum. In medicines, it acts as an emollient, lubricant, and moisture barrier to soften skin, reduce friction, and help prevent water loss from formulations.
2 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.- FDA label on DailyMed · label index refreshed Oct 3, 2026
- FDA openFDA NDC Directory · synced Oct 1, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
More NDCs from Viona Pharmaceuticals Inc labeler code 72578
- Nystatin and Triamcinolone Acetonide 100000 [USP'U]/g; 1 mg/g Ointment NDC 72578-088-01
- Nystatin 100000 U/g Ointment NDC 72578-089-01
- Triamterene and Hydrochlorothiazide 37.5 mg; 25 mg Capsule NDC 72578-090-01
- desoximetasone 2.5 mg/g Cream NDC 72578-091-01
- betamethasone dipropionate .5 mg/g Ointment NDC 72578-093-01
- Dapsone 75 mg/g Gel NDC 72578-094-01
- tizanidine 2 mg Tablet NDC 72578-096-06
- tizanidine 4 mg Tablet NDC 72578-097-06
- levofloxacin 250 mg Tablet, Film Coated NDC 72578-098-01
- levofloxacin 500 mg Tablet, Film Coated NDC 72578-099-01
- levofloxacin 750 mg Tablet, Film Coated NDC 72578-100-01
- Acyclovir 50 mg/g Cream NDC 72578-101-04
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- Drugs@FDA
Full prescribing information FDA SPL
🎯 Indications and Usage ▾
INDICATIONS AND USAGE Desoximetasone Ointment USP, 0.25% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
⏱️ Dosage and Administration ▾
DOSAGE AND ADMINISTRATION Apply a thin film of Desoximetasone Ointment USP, 0.25% to the affected skin areas twice daily. Rub in gently.
⛔ Contraindications ▾
CONTRAINDICATIONS Desoximetasone ointment, 0.25% is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.
⚠️ Warnings ▾
WARNINGS Keep out of reach of children.
🤒 Adverse Reactions ▾
ADVERSE REACTIONS The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae and miliaria. In controlled clinical studies the incidence of adverse reactions was low (0.3%) for Desoximetasone Ointment USP, 0.25% and consisted of development of comedones at the site of application.
To report side effects call Viona Pharmaceuticals Inc. at 1-888-304-5011 or FDA at 1-800-FDA-1088.
🤰 Pregnancy ▾
Pregnancy Teratogenic Effects Pregnancy Category C Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. Some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. Desoximetasone has been shown to be teratogenic and embryotoxic in mice, rats, and rabbits when given by subcutaneous or dermal routes of administration in doses 3 to 30 times the human dose of desoximetasone ointment USP, 0.25%.
There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, desoximetasone ointment USP, 0.25% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.
🧒 Pediatric Use ▾
Pediatric Use Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio. Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, and intracranial hypertension have been reported in pediatric patients receiving topical corticosteroids. Manifestations of adrenal suppression in pediatric patients include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation.
Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. Administration of topical corticosteroids to pediatric patients should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of pediatric patients.
Safety and effectiveness of Desoximetasone Ointment in pediatric patients below the age of 10 have not been established.
🆘 Overdosage ▾
OVERDOSAGE Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS ).
🧬 Clinical Pharmacology ▾
CLINICAL PHARMACOLOGY Topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids.
There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man. Pharmacokinetics The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. Topical corticosteroids can be absorbed from normal intact skin.
Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses.
Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys.
Some of the topical corticosteroids and their metabolites are also excreted into the bile. Pharmacokinetic studies in men with Desoximetasone Ointment USP, 0.25% with tagged desoximetasone showed no detectable level (limit of sensitivity: 0.003 •g/mL) in 1 subject and 0.004 and 0.006 •g/mL in the remaining 2 subjects in the blood when it was applied topically on the back followed by occlusion for 24 hours. The extent of absorption for the ointment was 7% based on radioactivity recovered from urine and feces.
Seven days after application, no further radioactivity was detected in urine or feces. Studies with other similarly structured steroids have shown that predominant metabolite reaction occurs through conjugation to form the glucuronide and sulfate ester.
📦 How Supplied / Storage and Handling ▾
HOW SUPPLIED Desoximetasone Ointment USP, 0.25% is supplied in 15 gram, 60 gram and 100 gram tubes. NDC 72578-095-01 in tube of 15 gm NDC 72578-095-02 in tube of 60 gm NDC 72578-095-03 in tube of 100 gm Storage Store at 20°-25°C (68° and 77°F); excursions permitted to 15-30°C (59-86°F) [See USP Controlled Temperature].
📋 Description ▾
DESCRIPTION Desoximetasone Ointment USP, 0.25% contains the active synthetic corticosteroid desoximetasone. The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and antipruritic agents. Each gram of Desoximetasone Ointment USP, 0.25% contains 2.5 mg of desoximetasone in an ointment base consisting of fractionated coconut oil and white petrolatum.
The chemical name of desoximetasone is Pregna-1, 4-diene-3, 20-dione, 9-fluoro-11, 21-dihydroxy-16-methyl-,(11b,16α)-. Desoximetasone has the molecular formula C 22 H 29 FO 4 and a molecular weight of 376.47. The CAS Registry Number is 382-67-2.
The structural formula is: structured product formula for Desoximetasone
⚠️ Precautions ▾
PRECAUTIONS Local Adverse Reactions with Topical Corticosteroids Local adverse reactions may be more likely to occur with occlusive use, prolonged use or use of higher potency corticosteroids. Reactions may include atrophy, striae, telangiectasias, burning, itching, irritation, dryness, folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, and miliaria. Some local adverse reactions may be irreversible.
Allergic Contact Dermatitis with Topical Corticosteroids Allergic contact dermatitis to any component of topical corticosteroids is usually diagnosed by a failure to heal rather than a clinical exacerbation. Clinical diagnosis of allergic contact dermatitis can be confirmed by patch testing. Concomitant Skin Infections Concomitant skin infections should be treated with an appropriate antimicrobial agent.
If the infection persists, desoximetasone ointment, 0.25% should be discontinued until the infection has been adequately treated. General Systemic absorption of topical corticosteroids can produce reversible hypothalamicpituitary-adrenal (HPA) axis suppression with the potential for clinical glucocorticosteroid insufficiency. This may occur during treatment or upon withdrawal of the topical corticosteroid.
Because of the potential for systemic absorption, use of topical corticosteroids may require that patients be periodically evaluated for HPA axis suppression. Factors that predispose a patient using a topical corticosteroid to HPA axis suppression include the use of more potent steroids, use over large surface areas, use over prolonged periods, use under occlusion, use on an altered skin barrier, and use in patients with liver failure. An ACTH stimulation test may be helpful in evaluating patients for HPA axis suppression.
If HPA axis suppression is documented, an attempt should be made to gradually withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid. Manifestations of adrenal insufficiency may require supplemental systemic corticosteroids. Recovery of HPA axis function is generally prompt and complete upon discontinuation of topical corticosteroids.
Cushing's syndrome, hyperglycemia, and unmasking of latent diabetes mellitus can also result from systemic absorption of topical corticosteroids. Use of more than one corticosteroid-containing product at the same time may increase the total systemic corticosteroid exposure. Pediatric patients may be more susceptible to systemic toxicity from use of topical corticosteroids.
Information for the Patient Patients using topical corticosteroids should receive the following information and instructions: This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes.
Patients should be advised not to use this medication for any disorder other than for which it was prescribed. The treated skin area should not be bandaged or otherwise covered or wrapped as to be occlusive unless directed by the physician. Patients should report any signs of local adverse reactions, especially under occlusive dressings.
Other corticosteroid-containing products should not be used with desoximetasone ointment USP, 0.25% without first consulting with the physician. As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within 4 weeks, contact the physician.
Laboratory Tests The following tests may be helpful in evaluating the hypothalamic-pituitary-adrenal (HPA) axis suppression: Urinary free cortisol test ACTH stimulation test Carcinogenesis, Mutagenesis, and Impairment of Fertility Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of topical corticosteroids. Desoximetasone was nonmutagenic in the Ames test. Pregnancy Teratogenic Effects Pregnancy Category C Corticosteroids have been shown to be teratogenic in laboratory… [Excerpted — this section continues on DailyMed.]
🍼 Nursing Mothers ▾
Nursing Mothers It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman.
🧬 Pharmacokinetics ▾
Pharmacokinetics The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption.
Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses. Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids.
Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.
Pharmacokinetic studies in men with Desoximetasone Ointment USP, 0.25% with tagged desoximetasone showed no detectable level (limit of sensitivity: 0.003 •g/mL) in 1 subject and 0.004 and 0.006 •g/mL in the remaining 2 subjects in the blood when it was applied topically on the back followed by occlusion for 24 hours. The extent of absorption for the ointment was 7% based on radioactivity recovered from urine and feces. Seven days after application, no further radioactivity was detected in urine or feces.
Studies with other similarly structured steroids have shown that predominant metabolite reaction occurs through conjugation to form the glucuronide and sulfate ester.
📄 Package Label / Principal Display Panel ▾
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL Desoximetasone Ointment USP, 0.25% NDC – 72578-095-01 15 gm tube Desoximetasone oinment, 0.25 carton label